Glenmark Pharmaceuticals Limited Stock: price and insider trades · India
No insider purchase over the last 90 days. The latest, by Robin Pinto, was filed 24 Nov 2021.
Since the insiders bought
- -19.5%Entry ₹529.30 · Close at T+365 ₹426.35
- -26.9%Entry ₹503.60 · Close at T+365 ₹368.00
- -24.9%Entry ₹512.00 · Close at T+365 ₹384.70
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Glenmark Pharmaceuticals Limited Buy (bullish), based on 11 analysts. Average price target: ₹2,512.82.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
- 1,000 shares@ ₹852.0066.7% of flowEquity SharesSEBI:7c43f029fcf65d701002d87cbc38f4b76c05691e
- 500 shares@ ₹851.0233.3% of flowEquity SharesSEBI:e66100d169abd1b49336835c9bcfd5956cdd6833
- 250 shares@ ₹490.192100.0% of flowEquity SharesSEBI:a283ff59f1d01e5f26fe4c410f3339b8dd4e629eCanonical exit: 21 Feb 2022 (T+90)
- 559 shares@ ₹535.6834100.0% of flowEquity SharesSEBI:ad6a757c300c502fcdefcf162081d13e883d157f
- 10,000 sharesEquity SharesSEBI:a1e94610183e8e27382d484204aff805092b4751
- 20,000 sharesEquity SharesSEBI:e06c089566a41c4b5ee160b60fbae8e1e10c0e7b
- 10,000 sharesEquity SharesSEBI:1511c0d568f366fa2576ec8a989296183f4d31d3
- 9,800 shares@ ₹513.015230.4% of flowEquity SharesSEBI:32da8d7c912f1d4d9db504832ae09f596a698347Canonical exit: 23 Dec 2021 (T+90)
- 1,950 shares@ ₹512.8651100.0% of flowEquity SharesSEBI:da3603681fcec6d45c53b1c6d36c6d3f53bdf9e4Canonical exit: 21 Dec 2021 (T+90)
- 7,800 shares@ ₹640.0029.5% of flowEquity SharesSEBI:fe9844636b32f99c393cfd6c43b8d98c8ab54355Canonical exit: 21 Sept 2021 (T+90)
- 2,800 shares@ ₹641.856110.6% of flowEquity SharesSEBI:8de2ea524f0611f5960938f5b20074c58d0281b6Canonical exit: 20 Sept 2021 (T+90)
- 7,870 shares@ ₹636.841629.5% of flowEquity SharesSEBI:cbe4bc773724e8e0f53f03e1d6508c57011868b5Canonical exit: 7 Sept 2021 (T+90)
12 of 12 declarations
About Glenmark Pharmaceuticals Limited
The three largest purchases in the record for Glenmark Pharmaceuticals Limited are by Glenn Mario Saldanha, for almost identical amounts: EUR 57,937 on September 24, 2021, EUR 56,385 on June 23, 2021 and EUR 56,334 on June 9, 2021. The filer has 4 purchases in all. This Indian health care company, listed on the Bombay stock exchange (market capitalisation of INR 623.8 billion, 49% held by insiders), totals 6 purchases worth EUR 203,926 (median EUR 38,284) and 3 sales worth EUR 17,936, or 67% purchases among open-market trades.
The sales are small: EUR 9,618 and EUR 4,804 for Praveen D Kurkal on September 20, 2023, EUR 3,514 for Sridhar Gorthi on November 15, 2021. Between September 22, 2021 and September 24, 2021, 2 filers bought for EUR 69,509.
Read moreShow less
Of 12 filings from 8 filers, 10 date from 2021 and 2 from 2023, with trades from June 9, 2021 to September 20, 2023. None falls in the last twelve months. The publication delay is a median of 1 day.
